Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-03-09
2008-09-02
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C514S012200
Reexamination Certificate
active
07419667
ABSTRACT:
A lactoferrin hydrolysate mixture or lactoferrin partial peptide that can be obtained by hydrolyzing lactoferrin with a hydrolytic enzyme and has an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer is used as an active ingredient of a drug for enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer.
REFERENCES:
patent: 5304633 (1994-04-01), Tomita et al.
patent: 5317084 (1994-05-01), Tomita et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 63-051337 (1988-03-01), None
patent: 5-238948 (1993-09-01), None
patent: 07-179355 (1995-07-01), None
patent: 07-309771 (1995-11-01), None
patent: 08-073499 (1996-03-01), None
patent: 08-291198 (1996-11-01), None
patent: 10-059864 (1998-03-01), None
patent: 63-186260 (1998-08-01), None
patent: 2000-229881 (2000-08-01), None
patent: WO 98/33509 (1998-08-01), None
patent: WO 00/12541 (2000-03-01), None
patent: WO 00/12542 (2000-03-01), None
Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000.
Lazar et al Molecular and Cellular Biology Mar 1988 vol. 8 No. 3 1247-1252.
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Translation of JP 2000-229881.
Trnaslation of JP 08-073499.
Database Caplus on Stn (2004) Abstract No. 2004:407504.
Notice of Reason for Rejection dated Sep. 5, 2006 issued to a related Japanese application with English translation.
Ogura M., Saishin Igaku, vol. 58, No. 12, pp. 102-121, 2003.
Current Immunology Illustrated, S. Koyasu, editor, pp. 41-43, 2003.
Hatake K.,Hematology Frontier, vol. 12, No. 11, pp. 65-71, 2002.
Smith, “Rituximab (monoclonal anti-CD20 antibody): Mechanisms of Action and Resistance,”Oncogene, vol. 22, pp. 7359-7368, 2003.
Berglund, et al. “A Rapid Analytical Technique for Flow Cytometric Analysis of Cell Viability Using Calcofluor White M2R,”Cytometry, vol. 8, No. 4, pp. 421-426, 1987.
Molecular Medicine, vol. 40, No. 10, pp. 1176-1181, 2003.
Eliassen, et al. “Enhanced Antitumour Activity of 15-Residue Bovine Lactoferricin Derivatives Containing Bulky Aromatic Amino Acids and Lipophilic N-Terminal Modifications,”Journal of Peptide Science, vol. 9, pp. 510-517, 2003.
Eliassen, et al. “Evidence for a Direct Antitumor Mechanism of Action of Bovine Lactoferricin,”Anticancer Research, vol. 22, pp. 2703-2710, 2002.
Iigo, et al. “INhibitory Effects of Bovine Lactoferrin on Colon Carcinoma 26 Lung Metastasis in Mice,”Clinical&Experimental Metastasis, vol. 17, pp. 35-40, 1999.
Sakurai, et al. “Rituximab ni yoru Hotai Isonsei no Saibo Shogai Sayo (CDC) ni Oyobosu Lactoferrin Bunkaibutsu (LFH) no Tenka Koka,” Rinsho Kesueki (Aug. 30, 2004), vol. 45, No. 8, p. 915, PS-2-186 with English translation.
Sakurai, et al. “Lactoferrin Bunkaibutsu (LFH) no Rituximab ni yoru Hotai Izonsei no Saibu Shogai Sayo (CDC) ni Oyobosu Tenka Koka,” vol. 63rd, p. 308, P-0799 with English translation, Sep. 29-Oct. 1, 2004.
Yoo, et al. “Bovine Lactoferrin and Lactoferricin, a Peptide Derived from Bovine Lactoferrin, Inhibit Tumor Metastasis in Mice,”Japanese Journal of Cancer Research, vol. 88, pp. 184-190, Feb. 1997.
Yoo, et al. “Apoptosis in Human Leukemic Cells Induced by Lactoferricin, a Bovine Milk Protein-Derived Peptide: Involvement of Reactive Oxygen Species,”Biochemical and Biophysical Research Communications, vol. 237, pp. 624-628, 1997.
Yoo, et al. “Bovine Lactoferrin and Lactoferricin™ Inhibit Tumor Metastasis in Mice,”Adv. Exp. Med. Biol., vol. 443, pp. 285-291, 1998.
International Search Report dated Jun. 22, 2005.
Office Action in counterpart Chinese Application No. CPCH 0564 808P.
Hatake Kiyohiko
Itoh Takehito
Mishima Yuji
Sakurai Takuma
Terui Yasuhito
Huff Sheela J
Knobbe Martens Olson & Bear LLP
Morinaga Milk Industry Co. Ltd.
LandOfFree
Drug for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983050